Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.

close  


Visit the News Hub

Common probiotic no help to young kids with stomach virus

Study examined children with diarrhea in nation’s emergency rooms

by Kristina SauerweinNovember 21, 2018

Mark Hallett/Huy Mach/Gaia Remerowski

Children with stomach viruses increasingly are given probiotics to ease symptoms of vomiting and diarrhea. But a major U.S. study led by Washington University School of Medicine in St. Louis shows that a commonly used probiotic is not effective in improving symptoms in young patients with gastroenteritis.

The findings are published Nov. 22 in The New England Journal of Medicine.

While rarely fatal in the United States, gastroenteritis — frequently yet erroneously called “stomach flu” — accounts for 1.7 million pediatric emergency room visits and more than 70,000 hospitalizations each year.

The study, involving nearly 1,000 children ages 3 months to 4 years, provides evidence against the popular and costly use of probiotics — live microorganisms believed to restore the balance of intestinal bacteria and boost the immune system.

“Probiotics have become an increasingly popular way to treat children experiencing acute gastroenteritis,” said the study’s lead author, David Schnadower, MD, who conducted the research as a Washington University professor of pediatrics and a physician at St. Louis Children’s Hospital. “Some smaller studies have indicated that probiotics may help, however, such studies had a number of limitations. We sought to provide independent and conclusive evidence for or against probiotic use in infants and toddlers with acute gastroenteritis.”

The researchers evaluated a common probiotic known as Lactobacillus rhamnosus GG, or LGG, which is sold over the counter as Culturelle. Certain versions of the probiotic are intended for babies and children.

A similar study in Canada, also published in the same issue of The New England Journal of Medicine and co-authored by Schnadower, evaluated effectiveness of a different probiotic — Lacidofil —  in children with gastroenteritis. The findings of that study, led by the University of Calgary Cumming School of Medicine in Alberta, mirrored those in the U.S. study.

“The results of the U.S. and Canadian studies were not ambiguous,” added the U.S. study’s co-author, Phillip I. Tarr, MD, Washington University’s Melvin E. Carnahan Professor of Pediatrics and director of the Pediatric Division of Gastroenterology, Hepatology and Nutrition. “Probiotics had no effect on the children,” Tarr said. “Parents are better off saving their money and using it to buy more fresh fruits and vegetables for their children.”

There are no treatments for pediatric acute gastroenteritis other than giving children fluids to prevent dehydration and, sometimes, medication to relieve nausea. The lack of options has prompted some physicians and parents to give ill children probiotics.

Probiotics generally are considered safe. However, the Food and Drug Administration (FDA) does not regulate dietary supplements such as probiotics as stringently as it does prescription and over-the-counter drugs. “Also, manufacturers of probiotics generally can claim that these microorganisms have positive health benefits without rigorous evidence to support their use,” Schnadower said.

Consumers worldwide spend billions of dollars each year on probiotic enriched foods, as well as over-the-counter supplements in pill and powder form. The researchers cited statistics showing that the global market for probiotics is predicted to expand in the United States from $37 billion in 2015 to $64 billion in 2023.

“Because of the popularity of probiotics, it was important to make sure their use is worth the cost,” said Schnadower, who is now the senior academic director of the Division of Emergency Medicine at Cincinnati Children’s Hospital Medical Center. “In this instance, probiotics added no measurable benefit, and, therefore, they are not worth the added cost.”

The U.S. study involved 971 children treated between July 2014 and June 2017 in the emergency departments at St. Louis Children’s and nine other geographically diverse U.S. academic medical centers. Participants were eligible if they had come to the emergency room with symptoms of gastroenteritis: watery stools, vomiting, diarrhea or other signs of acute intestinal infection. They also had to have not have taken probiotics in the preceding two weeks.

Half of the children in the study were randomly assigned to receive the probiotic LGG twice daily for five days, while the others took a similarly looking and tasting placebo. Otherwise, the children received standard clinical care.

Neither the researchers nor the parents knew which children had received the probiotics.

Regardless of whether the children took a placebo or probiotic, their symptoms and recovery were nearly identical. The data showed that diarrhea in both groups of kids lasted about two days and the kids missed an average of two days of day care.

“We tested many different scenarios — infants compared with toddlers, whether the patient had taken antibiotics, whether the gastroenteritis was caused by virus or bacteria, and how long the diarrhea had been going on before the treatment was given. We also had the probiotic independently tested for purity and strength. Every time, we reached the same conclusion,” Schnadower said. “LGG did not help.”

School of Medicine researchers Viani P. Dickey and Carla M. Hall-Moore also co-authored the study.

Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O’Connell KJ, Mahajan P, Levine AC, Bhatt SR, Roskind CG, Powell EC, Rogers AJ, Vance C, Sapien RE, Olsen C, Metheney M, Dickey VP, Hall-Moore C, Freedman SB. Lactobacillus rhamnosus GG versus Placebo for the Treatment of Acute Gastroenteritis in Children Presenting to Emergency Departments. The PECARN Probiotic Trial. The New England Journal of Medicine. Nov. 22, 2018.

This study was funded by the Eunice Kennedy Shriver National Institute for Child Health and Human Development of the National Institutes of Health (NIH), grant number R01HD071915. The Pediatric Emergency Care Applied Research Network (PECARN) is supported by the Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685.

Freedman is supported by the Alberta Children’s Hospital Foundation Professorship in Child Health and Wellness. Tarr is supported by the Washington University Digestive Diseases Research Core Center (P30DK052574).

The Food and Drug Administration granted an Investigational New Drug approval (IND#12371). iHealth Inc. provided L. rhamnosus GG and placebo capsules at no cost but had no involvement in the conduct or reporting of the trial.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Kristina covers pediatrics, surgery, medical education and student life. In 2020, she received a gold Robert G. Fenley Writing Award for general staff writing from the Association of American Medical Colleges (AAMC), and in 2019, she received the silver award. Kristina is an author and former reporter for the St. Louis Post-Dispatch and the Los Angeles Times, where she was part of a team of journalists that won the Pulitzer Prize in 2004 for breaking news. Additionally, she covered the 2014 Ferguson unrest for TIME magazine and, for eight years, wrote a popular parenting column for BabyCenter.com.